Molecular & Genetic Markers
IDH-mutant (tumor designation)
IDH-mutant designates a glioma carrying an IDH mutation, defining it as an astrocytoma or oligodendroglioma with a generally favorable outlook.
In short: IDH-mutant (tumor designation)
- It designates a glioma carrying an IDH mutation.
- These are astrocytomas or oligodendrogliomas.
- They generally have a more favorable outlook.
- They typically occur in younger adults.
What it is
"IDH-mutant" is the designation for a glioma that carries an IDH mutation. Among adult diffuse gliomas, IDH-mutant tumors are classified as astrocytomas (if they lack 1p/19q codeletion) or oligodendrogliomas (if they have it), and they generally have a more favorable outlook than IDH-wildtype tumors.
Understanding IDH-mutant (tumor designation)
When a diffuse glioma is found to carry an IDH mutation, this immediately places it in the more favorable category and narrows the diagnosis to either astrocytoma or oligodendroglioma based on additional testing (notably 1p/19q status). IDH-mutant gliomas typically affect younger adults, grow more slowly, and respond better to treatment than IDH-wildtype glioblastoma — though they are still serious tumors that usually require treatment and can transform to higher grades over time. The IDH-mutant designation also opens the option of IDH inhibitor therapy (such as vorasidenib) for certain grade 2 tumors. Because this designation shapes the entire approach, IDH testing is fundamental. Understanding the IDH-mutant designation clarifies what it means for a glioma to carry this favorable feature.
Why it matters
Understanding the IDH-mutant designation helps patients and families see that an IDH mutation places their tumor in the more favorable category — an astrocytoma or oligodendroglioma — with a generally better outlook and the possibility of targeted therapy.
Common questions
What does IDH-mutant designate?
A glioma carrying an IDH mutation.
What tumors are IDH-mutant?
Astrocytomas and oligodendrogliomas.
Is the outlook better?
Generally yes, compared with IDH-wildtype tumors.
Bottom line
IDH-mutant designates a glioma with an IDH mutation — an astrocytoma or oligodendroglioma — generally with a more favorable outlook and the option of targeted therapy.
Browse all 265 Glioma definitions
Read the Glioma patient guides
Not sure which page you need? Put words to it with the symptom navigator